Attention-Deficit/Hyperactivity Disorder Clinical Trial
— VEILLETDAHOfficial title:
Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity
Verified date | August 2017 |
Source | University Hospital, Bordeaux |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In a previous protocol, we highlighted an excessive daytime sleepiness at the Maintenance of
Wakefulness Tests (MWT) in 36% of adult Attention Deficit Disorder with or without
Hyperactivity (ADHD) patients. In 40% of cases this sleepiness was associated with a sleep
disorder objectified by polysomnography (PSG): apnea hypopnea syndrome (AHI) ≥ 10/h and / or
Periodicals Movements of Lower Limb (PLMI) ≥ 15/h. However, among patients with no sleep
disorder PSG, we can question the central origin of the Excessive Daytime Sleepiness. Thus,
we wish to determine potential changes in the regulation of sleep / wake cycle through a
protocol of extended wake.
The principal objective is to compare the objective sleepiness in sleepy patients with ADHD
and healthy subjects during a protocol of extended wake.
It's an observational study of interventional type realized in patient with ADHD syndrome
deprived of psychostimulant treatment (for 72 hours) and healthy subject, investigating the
implication of the homeostatic and circadian systems in the preservation of awakening.
Status | Completed |
Enrollment | 19 |
Est. completion date | August 2017 |
Est. primary completion date | May 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: For ADHD patient: - Patients male or feminine, from 18 to 50 years old, - Patient respondent in the criterion current diagnosis of the ADHD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-TR, - Meeting the criteria diagnosis of ADHD in the childhood, estimated by the interview " Conners'Adult ADHD Diagnostic Interview for DSM-IV " (CAADID), - Patient presenting a total score = 20 at CAARS With at least 6 items of money scales inattention or hyperactivity = 2, - Patients deprived of any psychostimulants for 72 hours, - Presenting at the polygraphy the absence of night-respiratory disorders (AHI < 10 / hour) and of Periodic Limbs Movements (PLMI < 15 / hour), as well as the absence of restless legs syndrome at the interview, - Presenting to the MWT an excessive daytime sleepiness: mean latency < 20 min, - Absence of syndrome of phase delay according to the criteria of l'ICSD2 (International Classification Sleep Disorders), - Having been schooled until class of 3rd, - Having regular schedules of life 4 days before going into the study, - Beneficiary of a national insurance scheme, - Having given in writing their informed consent to participate in the study. For healthy subject: - Patients male or feminine, from 18 to 50 years old, - Subjects not symptomatic of ADHD (Total score at the Wender Utah Rating Scale strictly lower than 46 on 25 questions concerning the ADHD, and less than four crosses in the more darker cases of first 6 questions of ASRS), - Subjects not presenting complaints of sleep, nor excessive daytime sleepiness (No item equal to 4 or 5 at Basic Nordic Sleep Questionnaire (BNSQ), excepted items 16 and 17 and total score at the Epworth Sleepiness Scale < 11), - Presenting at the polygraphy the absence of night-respiratory disorders (AHI < 10 / hour) and of Periodic Limbs Movements (PLMI < 15 / hour), as well as the absence of restless legs syndromeat the interview, - Not presenting to the MWT an excessive daytime sleepiness: mean latency > 34 min, - Absence of syndrome of phase delay according to the criteria of l'ICSD2 (International Classification Sleep Disorders), - Having been schooled until class of 3rd, - Having regular schedules of life 4 days before going into the study, - Beneficiary of a national insurance scheme, - Having given in writing their informed consent to participate in the study. Exclusion Criteria: - Posted or night work, - Any evolutionary affection (Brain tumour, epilepsy, migraine, cerebral vascular accident, calcifies, myoclonia, chorea, neuropathy, muscular dystrophies, dystrophy myotonic…), - Psychiatric comorbidity: Current major depressive episode, current hypo obsessive or obsessive episode, schizophrenia, - Renal disorders (Renal insufficiency, nephrolithiasis...), - Endocrine pathologies (dysthyroidism, diabetes), - Drug addiction during the last 6 months, - Alcohol addiction during the last 6 months, - Dependence in the tetra-hydroxy-cannabinol during the last 6 months, - Long-term treatment by benzodiazepines, - Treatment by atomoxetine, - Pregnant and breast-feeding women, - People under supervision, guardianship, - Person incapable to give personally its consent, - Nobody in emergency situation. |
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeaux | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of objective sleepiness | Comparison of objective sleepiness in sleepy patients with ADHD and healthy subjects during a protocol of extended wake. | at inclusion (day 0) | |
Secondary | Theta-alpha band of EEG sleep | Time constant and asymptotic value of the spectral power of the theta-alpha band of EEG sleep | At inclusion (Day 0) | |
Secondary | Amplitude and phase of internal temperature | At inclusion (day 0) | ||
Secondary | Score of Karolinska Sleepiness Scale (subjective measure of sleepiness) | At inclusion (day 0) | ||
Secondary | Results of the neuropsychological tests | Go/NoGO paradigm Continuous Performance Test and virtual Continuous Performance Test Stroop test and virtual stroop test Wisconsin Card Sorting Test |
At inclusion (day 0) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02251743 -
Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD
|
N/A | |
Completed |
NCT02226445 -
Treatment Drop-out and Missed Appointments Among Adults With ADHD
|
N/A | |
Completed |
NCT01342445 -
Effects of LDX on Functioning of College Students With ADHD
|
Phase 4 | |
Not yet recruiting |
NCT00391495 -
Inflammation in Children With Attention-Deficit/Hyperactivity Disorder
|
N/A | |
Completed |
NCT00528697 -
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00494819 -
Validity of ADHD Subtypes Using Neuropsychological Measure
|
N/A | |
Completed |
NCT01081132 -
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
|
Phase 3 | |
Completed |
NCT06064942 -
Multiple Family Narrative Therapy for Chinese Families of Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00391729 -
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00191048 -
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
|
Phase 4 | |
Terminated |
NCT00554385 -
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00997984 -
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
|
Phase 3 | |
Not yet recruiting |
NCT05568446 -
Social VR Based Intervention on Enhancing Social Interaction Skills in Children With AD/HD
|
N/A | |
Completed |
NCT02096952 -
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
|
Phase 4 | |
Recruiting |
NCT02623114 -
Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers
|
Phase 4 | |
Completed |
NCT01351246 -
Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT00686933 -
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00491647 -
Time Perception Deficits and Attention-Deficit/Hyperactivity Disorder
|
N/A | |
Completed |
NCT01081145 -
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
|
Phase 3 | |
Recruiting |
NCT06185985 -
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
|
Phase 4 |